MAETZOLD DEREK J sold $13K of CSTL
MAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 550 shares of CASTLE BIOSCIENCES INC (CSTL) at $22.92 on 2026-07-14 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO’s reported open-market sale of 550 shares at $22.92 on 2026-07-14, with holdings after the trade of 21,479 shares.
Market read
This provides a fresh, primary-source datapoint on insider selling, but the modest size and 10b5-1 structure reduce fundamental interpretability.
What to watch
Traders may over-weight small insider sales; the more informative signal would be changes in buying activity, larger transactions, or non-10b5-1 trades.
Background
The article is an SEC Form 4 insider transaction disclosure for CASTLE BIOSCIENCES, Inc.
Ticker impact
CASTLE BIOSCIENCES insider MAETZOLD DEREK J sold 550 shares on 2026-07-14 at $22.92 via a 10b5-1 plan, totaling $12,606.
Likely limited immediate price impact; any reaction would be sentiment-driven rather than fundamental.
The filing is a routine Form 4 insider sale with stated 10b5-1 pre-arrangement, and the disclosed dollar value is modest relative to company-level fundamentals.
Market effects
No sector-level read-across; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerCASTLE BIOSCIENCES INC
US-listed biotechnology company, ticker CSTL, subject of the Form 4 insider sale disclosure.
- insiderMAETZOLD DEREK J
President and Chief Executive Officer who executed the reported sale under a 10b5-1 plan.
